Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours (Q39217510)

24 February 2018

title

Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours (English)

1 reference

24 February 2018

author name string

Faidon-Marios Laskaratos

1

1 reference

24 February 2018

Martin Walker

2

1 reference

24 February 2018

Keval Naik

3

1 reference

24 February 2018

Emmanouil Maragkoudakis

4

1 reference

24 February 2018

Nikolaos Oikonomopoulos

5

1 reference

24 February 2018

Lee Grant

6

1 reference

24 February 2018

Tim Meyer

7

1 reference

24 February 2018

Martyn Caplin

8

1 reference

24 February 2018

Christos Toumpanakis

9

1 reference

24 February 2018

language of work or name

English

0 references

publication date

3 November 2016

1 reference

24 February 2018

British Journal of Cancer

published in

1 reference

24 February 2018

volume

115

1 reference

24 February 2018

issue

11

1 reference

24 February 2018

page(s)

1321-1327

1 reference

24 February 2018

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

copyright license

start time

1 November 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/bjc.2016.349

0 references

cites work

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129835

Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

21 August 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2016.349

Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2016.349

7 January 2021

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2016.349

7 January 2021

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2016.349

7 January 2021

High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2016.349

7 January 2021

Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2016.349

7 January 2021

Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2016.349

7 January 2021

Identifiers

DOI

10.1038/BJC.2016.349

1 reference

24 February 2018

release_hpqj2wu6sbht5p2bvt4xp6s37m

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hpqj2wu6sbht5p2bvt4xp6s37m

24 November 2022

mapped directly with Wikidata item

PMCID

5129835

1 reference

24 February 2018

PubMed ID

27811856

1 reference

24 February 2018